201 related articles for article (PubMed ID: 9750028)
21. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats.
Hirohashi T; Suzuki H; Ito K; Ogawa K; Kume K; Shimizu T; Sugiyama Y
Mol Pharmacol; 1998 Jun; 53(6):1068-75. PubMed ID: 9614210
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
Atsumi R; Okazaki O; Hakusui H
Biol Pharm Bull; 1995 Aug; 18(8):1114-9. PubMed ID: 8535406
[TBL] [Abstract][Full Text] [Related]
23. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.
Yamazaki M; Akiyama S; Ni'inuma K; Nishigaki R; Sugiyama Y
Drug Metab Dispos; 1997 Oct; 25(10):1123-9. PubMed ID: 9321514
[TBL] [Abstract][Full Text] [Related]
24. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
[TBL] [Abstract][Full Text] [Related]
26. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR).
Ishizuka H; Konno K; Naganuma H; Sasahara K; Kawahara Y; Niinuma K; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Mar; 280(3):1304-11. PubMed ID: 9067317
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein.
Yamada T; Kato Y; Kusuhara H; Lemaire M; Sugiyama Y
Biol Pharm Bull; 1998 Aug; 21(8):874-8. PubMed ID: 9743261
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats.
Masuda M; I'izuka Y; Yamazaki M; Nishigaki R; Kato Y; Ni'inuma K; Suzuki H; Sugiyama Y
Cancer Res; 1997 Aug; 57(16):3506-10. PubMed ID: 9270020
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
Lokiec F; Canal P; Gay C; Chatelut E; Armand JP; Roché H; Bugat R; Gonçalvès E; Mathieu-Boué A
Cancer Chemother Pharmacol; 1995; 36(1):79-82. PubMed ID: 7720181
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
32. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Guo S; Zhang X; Gan L; Zhu C; Gan Y
J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
[TBL] [Abstract][Full Text] [Related]
33. Effects of organic anions and bile acid conjugates on biliary excretion of pravastatin in the rat.
Fukumura S; Takikawa H; Yamanaka M
Pharm Res; 1998 Jan; 15(1):72-6. PubMed ID: 9487549
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
35. Effects of organic anions and bile acid conjugates on biliary excretion of LTC4 in the rat.
Kitaura K; Takikawa H; Yamanaka M
Prostaglandins; 1997 Nov; 54(5):745-55. PubMed ID: 9491205
[TBL] [Abstract][Full Text] [Related]
36. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
Chu XY; Suzuki H; Ueda K; Kato Y; Akiyama S; Sugiyama Y
J Pharmacol Exp Ther; 1999 Feb; 288(2):735-41. PubMed ID: 9918583
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of multidrug resistance (mdr) and canalicular multispecific organic anion transporter (cMOAT) genes following extrahepatic biliary obstruction in rats.
Kagawa T; Watanabe N; Sato M; Nakano A; Nishizaki Y; Hosoi K; Takashimizu S; Uchiyama J; Kimura M; Matsuzaki S
Biochem Mol Biol Int; 1998 Mar; 44(3):443-52. PubMed ID: 9556204
[TBL] [Abstract][Full Text] [Related]
38. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Gupta E; Safa AR; Wang X; Ratain MJ
Cancer Res; 1996 Mar; 56(6):1309-14. PubMed ID: 8640819
[TBL] [Abstract][Full Text] [Related]
40. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats.
Han YH; Kato Y; Watanabe Y; Terao K; Asoh Y; Sugiyama Y
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):394-400. PubMed ID: 11259322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
